Table 1.
Correlation between secreted USP25 levels in NSCLC patients and their clinicopathologic characteristics
| Clinical pathology |
USP25 levels (IHC) |
N | P value | ||
|---|---|---|---|---|---|
| –+ | + + | + + +-+ + + + | |||
| Gender |
|
|
|
|
|
| Male |
54(29.2) |
49(26.5) |
82(44.3) |
185 |
0.0066* |
| Female |
10(14.1) |
18(25.4) |
43(60.5) |
71 |
|
| Age |
|
|
|
|
|
| ≦63 |
30(21.9) |
34(24.8) |
73(53.3) |
137 |
0.0985 |
| >63 |
34(28.6) |
34(28.6) |
51(42.8) |
119 |
|
| Tumor size (cm) |
|
|
|
|
|
| <3.5 |
19(20.6) |
16(17.4) |
57(62) |
92 |
0.012* |
| 3.5-6 |
25(25) |
32(32) |
43(43) |
100 |
|
| >6 |
20(31.3) |
19(29.7) |
25(39) |
64 |
|
| Histological grade |
|
|
|
|
|
| Ι/Ι-Π |
15(36.6) |
13(31.7) |
13(31.7) |
41 |
0.0002* |
| Π |
33(27) |
38(31.1) |
51(41.9) |
122 |
|
| Π-Ш/Ш |
16(17.2) |
16(17.2) |
61(65.6) |
93 |
|
| Clinical Stage |
|
|
|
|
|
| 1AB |
26(41.3) |
12(19) |
25(39.7) |
63 |
0.0062* |
| 2AB |
23(20.4) |
35(31) |
55(48.7) |
113 |
|
| 3AB/4 |
15(18.7) |
20(25) |
45(56.3) |
80 |
|
| Lymph node status |
|
|
|
|
|
| Metastasis |
24(15.4) |
42(26.9) |
90(57.7) |
156 |
<0.0001* |
| No metastasis |
40(40) |
25(25) |
35(35) |
100 |
|
| Carcinoma |
|
|
|
|
|
| Primary |
64(25) |
67(26.2) |
125(48.9) |
256 |
<0.0001* |
| Adjacent | 132(51.6) | 123(48) | 1(0.4) | 256 | |
P value represents the probability from a chi-square test for tissue USP25 levels between variable subgroups, *P < 0.05.